- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01181453
Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers
May 16, 2018 updated by: Organogenesis
A Prospective, Multicenter, Randomized, Single-Blind, Phase III, Clinical Investigation of Dermagraft(R) in Patients With Plantar Diabetic Foot Ulcers
This study randomly assigns patients with diabetic foot ulcers to receive standard therapy (surgical debridement, saline-moistened gauze and offloading) alone or standard therapy plus Dermagraft(R).
Dermagraft is a device containing live human fibroblasts grown on an absorbable Vicryl mesh.
Patients are seen weekly until they heal or the 12-week treatment period is complete.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
314
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is 18 years of age or older.
- Patient has type I or II diabetes.
- Foot ulcer has been present for a minimum of 2 weeks under the current investigator's care.
- Foot ulcer is on the plantar surface of the forefoot or heel.
- Ulcer size is >/=1.0 cm2 at Day 0 (day of randomization).
- Ulcer extends through the dermis and into subcutaneous tissue but without exposure of muscle, tendon, bone, or joint capsule.
- Ulcer is free of necrotic debris, exhibits no signs of clinical infection, and appears to be made up of healthy vascularized tissue.
- Patient's Ankle-Arm Index by Doppler is >/=0.7.
- Patient has adequate circulation to the foot as evidenced by a palpable pulse.
- Female patients of child bearing potential must not be pregnant and must use accepted means of birth control.
- Patient and caregiver are willing to participate in the clinical study and can comply with the follow-up regimen.
- Patient or his/her legal representative has read and signed the Institutional Review Board (IRB) approved Informed Consent form before treatment.
- Patient's study ulcer has been present (open) for at least 6 weeks at the time of the Screening visit.
Exclusion Criteria:
- There is clinical evidence of gangrene on any part of the affected foot.
- The study ulcer is over a Charcot deformity.
- The study ulcer is due to a nondiabetic etiology.
- The ulcer has tunnels or sinus tracts that cannot be completely debrided.
- The ulcer is >20 cm2 (longest dimension cannot be greater than 5 cm).
- The ulcer has increased or decreased in size by 50% or more during the screening period.
- Presence of medical condition(s) that in the Investigator's opinion makes the patient an inappropriate candidate for this study.
- Presence of a malignant disease not in remission for 5 years or more.
- Evidence of severe malnutrition, based on a serum albumin level <2.0.
- Presence of patient having known alcohol or drug abuse.
- A random blood sugar reading >/=450 mg/dL.
- Presence of urine ketones that are noted to be "Small, Moderate, or Large".
- Presence of a nonstudy ulcer on the study foot within 7.0 cm of the study ulcer at Day 0.
- Use of oral or parenteral corticosteroids, immunosuppressive or cytotoxic agents, Coumadin or heparin during the study.
- A history of bleeding disorder.
- Presence of Acquired Immunodeficiency Syndrome (AIDS) or Human Immunodeficiency Virus (HIV).
- Participation in another study involving treatment with an investigational product within the previous 30 days.
- Elective osseous procedures to the study foot within 30 days prior to the Screening visit.
- Previous treatment with Dermagraft®.
- Presence in study ulcer of cellulitis, osteomyelitis or other clinical evidence of infection.
- Presence of condition(s) that seriously compromise the patient's ability to complete this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dermagraft(R)
Weekly application of Dermagraft(R) with standard care
|
Weekly application of Dermagraft(R) with standard care
Other Names:
|
OTHER: Standard care only
Weekly application of standard care
|
Weekly application of standard care
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Complete wound closure
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to reach complete wound closure
Time Frame: 12 weeks
|
12 weeks
|
Percent of wound closure by study end
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: William A Marston, MD, University of North Carolina School of Medicine, Chapel Hill, NC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 1998
Primary Completion (ACTUAL)
March 1, 2000
Study Completion (ACTUAL)
March 1, 2000
Study Registration Dates
First Submitted
August 12, 2010
First Submitted That Met QC Criteria
August 12, 2010
First Posted (ESTIMATE)
August 13, 2010
Study Record Updates
Last Update Posted (ACTUAL)
May 21, 2018
Last Update Submitted That Met QC Criteria
May 16, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ABH-DG-04-07-0798
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on Dermagraft
-
Shire Regenerative Medicine, Inc.CompletedVenous Leg UlcerUnited States, South Africa, Germany, Poland, Estonia, United Kingdom
-
OrganogenesisCompletedVenous Leg UlcerUnited States, United Kingdom, Poland, South Africa, Austria, Estonia, Germany, Sweden
-
U.S. Wound RegistryUnknownDiabetic Foot Ulcers | Pressure Ulcer | Surgical Wound Dehiscence | Venous Stasis Ulcer | Chronic Non Healing WoundUnited States
-
VA Office of Research and DevelopmentVA Northern California Health Care SystemCompletedDiabetic Foot UlcerUnited States
-
OrganogenesisCompletedDiabetic Foot UlcerUnited States
-
U.S. Wound RegistryEnrolling by invitationVenous Stasis Ulcer | Quality of Patient CareUnited States
-
Shire Regenerative Medicine, Inc.TerminatedEpidermolysis BullosaUnited States, Spain, Austria, Canada, France, Germany, Poland, Portugal
-
U.S. Wound RegistryAPMARecruitingDiabetic Foot Ulcer Outcome | Quality of Patient CareUnited States